Boston, MA – September 8, 2017: CSA Medical announces its upcoming mini-symposium at the European Respiratory Society (ERS) Conference, taking place on Sunday, September 10, 2017 at 5:30 pm in Milan, Italy. The symposium will highlight three month data from twelve patients in its feasibility study utilizing the RejuvenAir® Metered Cryospray™ System, which is under development for the treatment of chronic bronchitis.

The symposium will be chaired by Gerard Criner, MD (Philadelphia, USA). Felix Herth, MD (Heidelberg, DE), Dirk-Jan Slebos, MD (Groningen, NL), and Pallav Shah, MD (London, UK) will be presenting the RejuvenAir System and the feasibility data.

“This symposium marks a milestone in the RejuvenAir program, as this is the first time we are reporting on early results after the full treatment of patient’s airways. The information presented will convey how the rejuvenative properties of liquid nitrogen may be beneficial to chronic bronchitis patients.” said Ellen Sheets, MD, CEO CSA Medical.

Chronic bronchitis is a subset of Chronic Obstructive Pulmonary Disease (COPD). There are no treatments that address the underlying condition of Chronic Bronchitis, leading to an unmet medical need for this therapy. Chronic Bronchitis is associated with multiple clinical consequences, including the worsening of lung function decline, increasing risk of acute exacerbations of COPD, increased risk of developing pneumonia, reduced health related quality of life, and an increase in all-cause mortality.

About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze system which uses Liquid Nitrogen spray that has a boiling point of -196°C to ablate unwanted benign and malignant tissue. The RejuvenAir System is currently under clinical investigation and is not commercially available.

To learn more about our technology, please visit www.csamedical.com.

###